CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.



    
    Unique hemostatic powder is available in ready-to-use applicator

    
    ATLANTA, Sept. 22 /CNW/ -- CryoLife, Inc. (NYSE:   CRY), a biomaterials,
medical device and tissue processing company, announced today that it has
begun distribution in Canada, through Sorin Group Canada, Inc., of Hemostase
MPH to control bleeding in general, cardiac and vascular surgery.
    CryoLife began distributing Hemostase MPH in the U. S., the United
Kingdom and Germany in the second quarter of 2008.  Distribution will continue
to expand to additional markets later in 2008 and in 2009.
    Hemostase MPH is developed using Microporous Polysaccharide Hemospheres
technology (MPH(R)), which produces a plant-based powder that rapidly
dehydrates blood, and enhances clotting on contact.  The Hemostase MPH product
received Health Canada approval in 2002, CE Mark approval in 2003, and FDA
pre-market approval in 2006.
    Available in a convenient ready-to-use applicator, Hemostase MPH, unlike
many hemostatic agents, does not require additional operating room preparation
or special storage conditions.  In addition, pre-clinical studies have shown
that Hemostase MPH does not promote infection and absorbs within 24-48 hours
of application at the wound site, compared to other surgical hemostats which
can take 3-8 weeks or more to fully break down.
    "Hemostase MPH is complementary to our BioGlue(R) surgical adhesive
products.  It provides surgeons with the ability to quickly and confidently
control active bleeding during surgery," stated Steven G. Anderson, president
and chief executive officer.  "We are pleased to be able to offer this product
in Canada through the Sorin Group."
    
    About CryoLife, Inc.
    
    Founded in 1984, CryoLife, Inc. is a leader in the processing and
distribution of implantable living human tissues for use in cardiac and
vascular surgeries throughout the U.S. and Canada.  The Company recently
received FDA clearance for the CryoValve(R) SG pulmonary human heart valve,
processed using CryoLife's proprietary SynerGraft(R) Technology.  The
Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to
sutures and staples for use in adult patients in open surgical repair of large
vessels.  BioGlue is also CE marked in the European Community and approved in
Canada and Australia for use in soft tissue repair.  CryoLife distributes
Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac
and vascular surgery and in the United Kingdom, Germany, France and Canada for
cardiac, vascular, and general surgery, subject to certain exclusions.  The
Company also distributes the CryoLife-O'Brien(R) Stentless Porcine Aortic
Bioprosthesis, which is CE marked for distribution within the European
Community.
    Statements made in this press release that look forward in time or that
express management's beliefs, expectations or hopes are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995.  These statements include those regarding the ability of the Company
to begin distributing the Hemostase MPH product when expected and the
anticipated benefits of Hemostase MPH.  These future events may not occur as
and when expected, if at all, and, together with the Company's business, are
subject to various risks and uncertainties.  These risks and uncertainties
include that the Company may be unable to effectively leverage its existing
sales force to sell Hemostase MPH, that surgeons may not choose to utilize
Hemostase MPH, that Hemostase MPH may not perform in accordance with
preliminary tests and results and that other distributors of the product may
impede the Company's ability to sell to new or existing customers.  These
risks and uncertainties also include the risk factors detailed in CryoLife's
Securities and Exchange Commission filings, including CryoLife's Form 10-K
filing for the year ended December 31, 2007 and the Company's other SEC
filings.  The Company does not undertake to update its forward-looking
statements.
    For additional information about the company, visit CryoLife's Web site
    
                           http://www.cryolife.com
    

    
    Media Contacts:
    

    
    D. Ashley Lee
    Executive Vice President, Chief Financial Officer and
    Chief Operating Officer
    Phone: 770-419-3355
    

    
    Katie Brazel
    Fleishman Hillard
    Phone: 404-739-0150

    




For further information:

For further information: D. Ashley Lee of CryoLife, Inc., Executive Vice
President, Chief Financial Officer and Chief Operating Officer,
+1-770-419-3355; or Katie Brazel, Fleishman Hillard, +1-404-739-0150, for
CryoLife, Inc. Web Site: http://www.cryolife.com

Organization Profile

CRYOLIFE, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890